Home > Gastroenterology > ECCO 2020 > Short- and Long-Term Treatment Results > Subcutaneous ustekinumab as maintenance therapy in UC

Subcutaneous ustekinumab as maintenance therapy in UC

Presented By
Dr R. Panaccione & Dr W.J. Sandborn
Conference
ECCO 2020
Trial
UNIFI
The efficacy of ustekinumab through 92 weeks in patients with moderate-to-severe ulcerative colitis (UC) who had been randomised in the UNIFI maintenance study was presented [1]. This study evaluated subcutaneous ustekinumab through 1 year in responders to intravenous ustekinumab induction. Patients who completed the maintenance study could enter a long-term extension (LTE) through 220 weeks. During the LTE, participants were eligible to receive dose adjustment (every 12 weeks [Q12W] to every 8 weeks [Q8W] or sham dose adjustment of Q8W to Q8W) starting at week 56. Symptomatic remission (stool frequency subscore of 0 or 1 and rectal bleeding subscore of 0) and partial Mayo remission (partial Mayo score ≤2) were evaluated through week 92. When dose adjustment was considered to be part of the treatment experience (i.e., not a treatment failure), ustekinumab efficacy was maintained through 2 years of treatment. Of patients randomised to Q12W and Q8W, 66.1 % a...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on